Ro turned telehealth into an upgrade

Ro’s early breakthrough was turning a stigmatized, inconvenient medical errand into something that was cheaper, faster, and easier than going to a clinic. For ED and hair loss, the patient usually did not need a physical exam, wanted privacy, and already knew the outcome they were seeking. Ro collapsed search, intake, doctor review, prescription, and delivery into one flow, so telehealth felt like an upgrade, not a compromise.1 2

• The business model matched that experience. Ro made the consult effectively free, then earned money on the recurring prescription, which let it undercut a normal visit plus pharmacy copay. In practice, the consumer bought a monthly medicine subscription, not a one time doctor appointment.1
• This worked best in narrow categories where embarrassment and delay were part of the pain. That is why Ro and Hims both started in men’s health, while later telehealth players used the same playbook in other high intent niches like mental health, fertility, and hormones.1 3 4
• The limit of the wedge is that a great checkout flow does not by itself create lasting healthcare breadth. Ro’s later growth required moving beyond ED into broader categories, because core subscription telehealth products can see high churn and rising ad costs once competitors copy the same acquisition funnel.1 2

The next phase of consumer telehealth is less about proving people will buy care online, and more about building longer lived care relationships. The winners are likely to be the companies that turn a one problem prescription purchase into repeat care across adjacent conditions, with stronger retention, broader treatment categories, and lower dependence on paid ads.1 2 4